A high-resolution image of human egg cells. (Jezper, via Shutterstock)California’s plan to create an ambitious, $150 million public/private partnership to commercialize state-funded stem cell research edged forward this week as the deadline for applications closed on Monday afternoon. Little is known about the nature of the applications — not even the number received.
An illustration of a telomere at the end of a DNA sequence of a chromosome. (Illustration: VIT Studio, via Shutterstock) The $3 billion California stem cell agency this week welcomed the first members of its “Great Ideas” club and gave them a total of nearly $4 million to pursue the scientific gleams in their eyes. Nineteen researchers received awards at a meeting yesterday of the governing board of the agency. They were the first such grants approved by the nearly 12-year-old enterprise.
A scientist works in a biological laboratory. (Photo: Anya Ivanova, via Shutterstock)A new stem cell company that targets cancer by unleashing an “eat me” trigger has emerged from a $30 million investment by the state of California. Creation of the Palo Alto firm, which is called Forty Seven, Inc., was announced Feb. 24 by its backers and its key researcher, Irv Weissman, director of Stanford University’s stem cell program.
Headquarters of the state controller, Sacramento. (Photo: Coolcaesar)David Evans, a largely unknown Republican candidate in the race for state controller, emerged from obscurity and achieved stunning results on a $600 campaign budget against three established politicians, leaving analysts struggling to interpret the implications of the results.